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1. Introduction 
Substance P (SP), an undecapeptide amide, is the 
hypotensive, spasmogenic agent detected [l], the 
sialogogic peptide noticed in [2], and the moto- 
neuron-depolarizing peptide studied [3]. Complete 
amino acid sequence of SP was determined [4,S] 
. (fig.la). Its primary structure was confirmed by 
synthesis either by the solid-phase method [4,6,7] or 
conventional solution techniques [8-lo]. 
Studies on the relationship between chainlength 
and activity revealed that the C-terminal heptapeptide 
of SP exhibited higher contractile activity on the 
isolated guinea pig ileum than that of synthetic SP 
[7,9]:Thus, in an effort to identify sites involved in 
the receptor recognition and activation of SP, the N- 
glutamine residue of the C-terminal heptapeptide of 
this hormone has been modified by replacing its car- 
boxamide hydrogen atoms by methyl groups (fig.1 b). 
This modification of the -NH2 portion of the 
carboxamide group renders it less hydrophilic and 
possibly less available to the receptor due to steric 
hindrance. 
a H-hrq-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-~let-NH~ 
12 3 4 5 6 7 8 9 10 11 
b H-Glu N(CHx)z -Gin-Phe-Phe-Gly-Leu-Met-NH2 
5 6 7 8 9 10 11 
Fig.l.(a) Amino acid sequence of substance P (SP). (b) 
[5-fl-dimethyl)-glutamine] C-terminal heptapeptide of SP; 
numbers indicate sequence positions of individual residues. 
Amino acids, with the exception of glycine, are of the 
L-configuration. 
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2. Experimental 
The synthetic route chosen is based on the coupling 
of the appropriate pentapeptide with the C-terminal 
H-Leu-Met-NH, part of the molecule. The penta- 
peptide derivative, boc-(N’-dimethyl)Gln-Gln- 
Phe-Phe-Gly-OBzl, was constructed stepwise 
starting from glycine benzylester p-toluenesulphonate 
[ 1 l] and using the N-fert butyloxycarbonyl (hoc) 
group for the a-amino protection and DCC, 
1 -hydroxybenzotriazole [ 121 for activation. boc-(N’- 
dimethyl)-L-glutamine m.p. 124-125’C (from ethyl 
acetate), [a]g t 2.2”C (c 1, EtOH) was prepared 
from p -dimethyl-L-glutamine [ 131 using S-boc4,6- 
dimethyl-2.mercapto-pyrimidine [141 as the acylating 
agent. 
The obtained pentapeptide benzyl ester was 
catalytically hydrogenated to yield the corresponding 
acid, boc-(N’-dimethyl)Gln-Gln-Phe-Phe-Gly-OH, 
m.p. 183-185”C, [o]g -23.9’C (c 0.5, DMF), which 
was then condensed with H-Leu-Met-NH* [ 151 
by the DCC, 1 -hydroxybenzotriazole method [ 121. 
The resulting heptapeptide derivative, boc4p- 
dimethyl)Gln-Gln-Phe-Phe-Gly-Leu-Met-NHZ, 
m.p. 218-222”C, [(Y]E -3S.9”C (c 0.5, DMF), was 
deprotected with CF&OOH, desalted on a ion- 
exchange resin (Dowex-1X8) using ethanol as the 
eluent and purified by gel-filtration on Sephadex 
G-15 with 50% acetic acid to give the desired 
analogue. Amino acid analysis gave the following 
molar ratios: Glu, 2.03; Phe, 2.05; Gly, 1 .OO; Leu, 
1.02; Met, 0.91; NHs, 1.98. It had m.p. 234-238°C 
(dec.) and [~]g -56°C (c 0.18, DMF). Calc. for 
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C43H64Nn,09S: C, 57.57; H, 7.19; N, 15.61%. 
Found: C, 57.79; H, 6.98; N, 15.74. Thin-layer 
chromatography of the analogue showed one spot 
RF 0.40 in n-BuOH-AcOH-Hz0 (4: 1: I), RF 0.75 in 
n-BuOH-AcOH-H,O-pyridine (30:6:24:20) and 
RF 0.32 in n-BuOH-AcOH-Hz0 (4: 1: 5, upper 
phase). Thin-layer chromatograms were done on silica 
gel plates with sample loads of 20-50 pg, and were 
revealed by reaction with ninhydrin and chlorine- 
tolidine reagent. 
3. Results and discussion 
The analogue was tested on the isolated guinea pig 
ileum and has an agonistic activity 25% of the activity 
of SP. When the analogue was tested at 5 X 10e7 M 
(maximal contraction) then the contraction of the 
ileum produced by SP was inhibited by -30%. Thus 
the analogue has a weak agonistic and also a weak 
antagonistic activity. 
These results may suggest hat the hydrogens of 
the IV’-amide portion of the N-terminal glutaminyl 
side chain are not themselves essential from a con- 
formational standpoint for the biologically active 
model of the hormone. Considering that pGlu-Cln- 
Phe-Phe-Gly-Leu-Met-NH2 [ 161 is more 
active than substance P, while our [5@‘-dimethyl)- 
glutamine]-analogue has a weak activity, it is rather 
tempting to assume that the carbonyl group of the 
carboxamide of glutamine at position 1 of the 
C-terminal heptapeptide of substance P (position 5 
for substance P) which is sterically hindered in the 
methyl-substituted heptapeptide, might be an 
essential ‘element’ for biological response on the 
isolated guinea pig ileum. 
Finally, it should be mentioned that specific 
competitive inhibitors of SP would be extremely 
useful, but none is yet available. Although it is 
known for SP that its continued presence or of an- 
other tachykinin in the bath reduces the response of 
the isolated smooth muscle to subsequent application 
[ 17,181, it seems likely that a proper modification of 
the carboxamide portion of the [5-(p-dimethyl) 
glutamine]-analogue may afford a more potent 
antagonist. 
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